Cargando…

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the overall response rate (ORR) of which in the B-NHL patients is much lower compared to the patients with r/r B acute lymphoblastic leukemia (B-AL...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Yuan, Deng, Biping, Rong, Luan, Li, Chuo, Song, Weiliang, Ling, Zhuojun, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Chang, Alex H., Feng, Xiaoming, Xiong, Xiujuan, Chen, Xiaoli, Pan, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279746/ https://www.ncbi.nlm.nih.gov/pubmed/34277400 http://dx.doi.org/10.3389/fonc.2021.640166

Ejemplares similares

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Ruxolitinib mitigates steroid‐refractory CRS during CAR T therapy
por: Pan, Jing, et al.
Publicado: (2020)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL
por: Zurko, Joanna, et al.
Publicado: (2022)

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
por: Tan, Yue, et al.
Publicado: (2023)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
por: Zhang, Jiqin, et al.
Publicado: (2022)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL
por: Korell, Felix, et al.
Publicado: (2020)

Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy
por: Bezerra, Evandro D., et al.
Publicado: (2022)

Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells
por: Yang, Fei, et al.
Publicado: (2019)

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
por: Liu, Shuangyou, et al.
Publicado: (2020)

Mediport use as an acceptable standard for CAR T cell infusion
por: Eylon, Maya, et al.
Publicado: (2023)

CAR(+) and CAR(−) T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies
por: Louie, Raymond Hall Yip, et al.
Publicado: (2023)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
por: Zheng, Peihao, et al.
Publicado: (2023)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
por: Katz, Steven, et al.
Publicado: (2016)

Sequential CAR T cell and targeted alpha immunotherapy in disseminated multiple myeloma
por: Awuah, Dennis, et al.
Publicado: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Motor Cars for Doctors: Cars Suitable for Practitioners
Publicado: (1906)

1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)

P1380: THE COMPOSITION OF INFUSED CD19-CAR-T PRODUCT IMPACTS ON EFFICACY
por: Bellesi, Silvia, et al.
Publicado: (2023)

CERN cars at car sharing point on the Meyrin site
por: Andrade, Rui
Publicado: (2022)

Motor Cars for Doctors: Hints on Buying a Car
Publicado: (1906)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy
por: Li, Hongjun, et al.
Publicado: (2021)

Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies
por: Luo, Weichuan, et al.
Publicado: (2022)

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment
por: Zhu, Chaojie, et al.
Publicado: (2023)

Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity
por: Breen, William G., et al.
Publicado: (2023)

Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
por: Rejeski, Kai, et al.
Publicado: (2023)

Il-6 is non-essential to murine CD19 CAR efficacy, but can mediate acute GVHD following allogeneic BMT with CAR T cell infusion
por: Jacoby, Elad, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t21etre2vm6eq3sf1d8785mrcp